MedPath

Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION

Not Applicable
Completed
Conditions
Dry Eye
Interventions
Device: SYSTANE HYDRATION lubricant eye drops
Device: Hyabak 0.15% eye drops
Drug: 0.9% saline eye drops
Registration Number
NCT02470429
Lead Sponsor
Alcon Research
Brief Summary

The purpose of this study is to compare SYSTANE® HYDRATION to Hyabak 0.15% based on total ocular surface staining scores (TOSS) at Day 42.

Detailed Description

Subjects will first be dispensed preservative-free 0.9% saline eye drops (saline eye drops) to be used during the Run-in phase between Screening Visit and Day 0 (Visit 1). Subjects who qualify will be randomized in a 1:1 manner to receive either treatment with SYSTANE® HYDRATION Lubricant Eye Drops or Hyabak 0.15% Eye Drops.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
114
Inclusion Criteria
  • Willing and able to attend all study visits;
  • Use of non-BAK (Benzalkonium Chloride) artificial tears at least once a day, for at least 3 months prior to Screening Visit;
  • Diagnosis of Dry Eye (by a health care professional) for at least 3 months prior to Screening Visit;
  • Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
  • Women of childbearing potential who are pregnant or breast feeding;
  • Any hypersensitivity to the use of the study products or an allergy to any ingredient(s) contained within study products;
  • Ocular abnormalities in either eye that could adversely affect the safety or efficacy outcome;
  • Active ocular infection (bacterial, viral, or fungal) or active inflammation not associated with dry eye;
  • Use of chronic systemic medications: (prescription, over the counter, vitamins/supplements) on a stable dose for less than 30 days prior to Screening Visit, or any anticipated change in dosing regimen during the course of the study;
  • History of ocular or intraocular surgery or serious ocular trauma in either eye within 6 months prior to Screening Visit;
  • Any medical condition (systemic or ophthalmic) that may, in the opinion of the Investigator, preclude the safe administration of study products or safe participation in the study;
  • Use of any topical ocular over-the-counter or prescribed medications in either eye (with the exception of artificial tears/gels/ lubricants) 2 weeks prior to Screening Visit;
  • Contact lens use within 2 weeks prior to Screening Visit and unwilling to avoid contact lens use during the course of the study;
  • Unwilling to avoid the use of additional artificial tears (other than the study products) throughout the study;
  • Other protocol-defined exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SYSTANE HYDRATIONSYSTANE HYDRATION lubricant eye dropsSYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
SYSTANE HYDRATION0.9% saline eye dropsSYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
Hyabak 0.15%Hyabak 0.15% eye dropsHyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
Hyabak 0.15%0.9% saline eye dropsHyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 42Baseline (Day 0), Day 42

The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator graded 3 areas of the ocular surface for dryness on a scale from 0 to 5, where 0=Absent and 5=Severe. The 3 scores were summed for a resultant overall 0-15 score. A more negative change value indicates greater efficacy. One eye (study eye) contributed to the analysis.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in IDEEL Treatment Effectiveness Score at Day 42Baseline (Day 0), Day 42

The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.

Change From Baseline in IDEEL Treatment Inconvenience Score at Day 42Baseline (Day 0), Day 42

The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 satisfaction score was calculated, with a higher score indicating greater satisfaction and less treatment-related bother.

Change From Baseline in Tear Film Break-up Time (TFBUT) at Day 42Baseline (Day 0), Day 42

TFBUT is defined as the time elapsed from the last blink until 1 or more dry spots appeared in the precorneal tear film. A longer tear film break-up time indicates a more stable tear film and may lead to improvement in dry eye symptoms. One eye (study eye) contributed to the analysis.

© Copyright 2025. All Rights Reserved by MedPath